Sarepta Therapeutics Securities Class Action
Sarepta Therapeutics · Elevidys gene therapy · Ongoing Litigation
About this case
A federal securities class action alleges that Sarepta Therapeutics and certain officers and directors made misleading statements concerning ELEVIDYS, AAVrh74-based therapies, limb-girdle muscular dystrophy treatments, and the ESSENCE trial, causing investor losses. The amended complaint is pending, and the defendants moved to dismiss; oral argument on that motion occurred on August 4, 2026, so the litigation remains ongoing.
Case overview
- Defendant company
- Sarepta Therapeutics
- Product or service
- Elevidys gene therapy
- Case name
- In re Sarepta Therapeutics Securities Litigation
- Court case number
- 1:25-cv-13530
- Case status
- Ongoing Litigation
- Lawsuit type
- Securities
- Reported harm
- Misrepresentation
Participation information
KSF Sarepta shareholder inquiry
Shareholders or others with information about Sarepta, including long-term holders of Sarepta shares, may contact Kahn Swick & Foti regarding the investigation.
Visit the law firm’s case page to learn more or contact Kahn Swick & Foti.
- Type
- Law Firm Signup
Sources
- Sarepta Therapeutics Securities Class Action
Barchart.com ·
- Sarepta Therapeutics Securities Litigation
STL.News ·